An official website of the United States government
Home
Name
Avapritinib
Alternate Names
Ayvakit
Abbreviations
None
Category
Chemotherapy
Subcategory
kinase inhibitor
NSC Number
None
Primary Site
None
Histology
GIST
Remarks
June 21, 2021 FDA approved avapritinib for treatment of systemic mastocytosis with an associated hematological neoplasm and mast cell leukemia
January 10, 2020 The FDA approved Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST). Ayvakit is a kinase inhibitor, meaning it blocks a type of enzyme called a kinase and helps keeps the cancer cells from growing.
January 10, 2020 The FDA approved Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST). Ayvakit is a kinase inhibitor, meaning it blocks a type of enzyme called a kinase and helps keeps the cancer cells from growing.
Coding
This drug should be coded
